Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...

In early phase trials innovative designs offer potential for improvements in efficiency and decision-making. Determining the ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Download ...

A multicenter collaboration led by the Bellvitge Biomedical Research Institute (IDIBELL) - Institut Català d'Oncologia (ICO) ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...

BioAge has also entered a strategic collaboration with Lilly ExploR&D (part of Lilly Catalyze360) to discover two therapeutic antibodies that address novel metabolic aging targets identified by BioAge ...

Investors continue to flock to pharma services, targeting opportunities across the range of providers to the ...